Lrig2-Deficient Mice Are Protected against PDGFB-Induced Glioma
Open Access
- 4 September 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (9) , e73635
Abstract
The leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins constitute an integral membrane protein family that has three members: LRIG1, LRIG2, and LRIG3. LRIG1 negatively regulates growth factor signaling, but little is known regarding the functions of LRIG2 and LRIG3. In oligodendroglial brain tumors, high expression of LRIG2 correlates with poor patient survival. Lrig1 and Lrig3 knockout mice are viable, but there have been no reports on Lrig2-deficient mice to date. Lrig2-deficient mice were generated by the ablation of Lrig2 exon 12 (Lrig2E12). The Lrig2E12-/- mice showed a transiently reduced growth rate and an increased spontaneous mortality rate; 20-25% of these mice died before 130 days of age, with the majority of the deaths occurring before 50 days. Ntv-a transgenic mice with different Lrig2 genotypes were transduced by intracranial injection with platelet-derived growth factor (PDGF) B-encoding replication-competent avian retrovirus (RCAS)-producing DF-1 cells. All injected Lrig2E12+/+ mice developed Lrig2 expressing oligodendroglial brain tumors of lower grade (82%) or glioblastoma-like tumors of higher grade (18%). Lrig2E12-/- mice, in contrast, only developed lower grade tumors (77%) or had no detectable tumors (23%). Lrig2E12-/- mouse embryonic fibroblasts (MEF) showed altered induction-kinetics of immediate-early genes Fos and Egr2 in response to PDGF-BB stimulation. However, Lrig2E12-/- MEFs showed no changes in Pdgfrα or Pdgfrβ levels or in levels of PDGF-BB-induced phosphorylation of Pdgfrα, Pdgfrβ, Akt, or extracellular signal-regulated protein kinases 1 and 2 (ERK1/2). Overexpression of LRIG1, but not of LRIG2, downregulated PDGFRα levels in HEK-293T cells. The phenotype of Lrig2E12-/- mice showed that Lrig2 was a promoter of PDGFB-induced glioma, and Lrig2 appeared to have important molecular and developmental functions that were distinct from those of Lrig1 and Lrig3.Keywords
This publication has 40 references indexed in Scilit:
- Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signallingNature Cell Biology, 2012
- The Pan-ErbB Negative Regulator Lrig1 Is an Intestinal Stem Cell Marker that Functions as a Tumor SuppressorCell, 2012
- Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast CancerMolecular Cancer Research, 2011
- Identifying common prognostic factors in genomic cancer studies: A novel index for censored outcomesBMC Bioinformatics, 2010
- Lrig1 Expression Defines a Distinct Multipotent Stem Cell Population in Mammalian EpidermisCell Stem Cell, 2009
- Alterations in cell growth and signaling in ErbB3 binding protein-1 (Ebp1) deficient miceBMC Cell Biology, 2008
- Reduced body weight is a common effect of gene knockout in miceBMC Genomic Data, 2008
- Loss of Arf causes tumor progression of PDGFB-induced oligodendrogliomaOncogene, 2007
- LRIG1 Is a Novel Negative Regulator of the Met Receptor and Opposes Met and Her2 SynergyMolecular and Cellular Biology, 2007
- Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescenceProceedings of the National Academy of Sciences, 2006